医学
不良事件报告系统
怀孕
产科
优势比
不利影响
前瞻性队列研究
引产
药物警戒
内科学
妊娠期
置信区间
肌酐
脐带
新生儿低血糖
糖尿病
重症监护医学
子痫前期
妊娠期糖尿病
数据库
胎儿
剖腹产
药物流行病学
低出生体重
药品
作者
Xianyan Yan,Hunong Xiang,Jingzhong Ou,Li Pan,Xiaoyan Wang,Liping Liu,Yuanling Zhou,Yan Li,Ronghua Zhang,Yanping Wu
标识
DOI:10.1177/00185787261433433
摘要
Objective: To evaluate the adverse event profile and potential safety signals associated with glyburide use during pregnancy using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Data from FAERS (Q1 2015-Q1 2025) were analyzed. Pregnant cases and glyburide exposures were identified using standardized MedDRA terminology. Signal detection was conducted using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS) algorithms. Results: A total of 284 712 pregnant women were included, among whom 164 used glyburide. Seventeen positive safety signals were detected. Hypoglycaemia neonatal, congenital anomaly in offspring, and maternal hypoglycaemia were consistent with drug labeling and previous reports. Additional newly identified signals included caesarean section, placenta praevia, amniotic fluid volume decreased, blood creatinine increased, hypoxia, metabolic acidosis, umbilical cord abnormality, and others. At the system organ class (SOC) level, positive signals were observed for metabolism and nutrition disorders, endocrine disorders, and pregnancy, puerperium and perinatal conditions. Conclusion: This real-world FAERS-based analysis suggests that glyburide use during pregnancy may be associated with various adverse metabolic and pregnancy-related outcomes. Caution is warranted when prescribing glyburide for patients with HIP, with particular attention to monitoring placental function and neonatal glucose levels. Further prospective studies are needed to validate these findings.
科研通智能强力驱动
Strongly Powered by AbleSci AI